Quéro L, Guillerm S, Hennequin C. Neoadjuvant or adjuvant therapy for gastric cancer. World J Gastrointest Oncol 2015; 7(8): 102-110 [PMID: 26306142 DOI: 10.4251/wjgo.v7.i8.102]
Corresponding Author of This Article
Laurent Quéro, MD, PhD, Department of Radiation Oncology, Saint Louis Hospital, 1 Avenue Claude Vellefaux, 75010 Paris, France. laurent.quero@sls.aphp.fr
Research Domain of This Article
Oncology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Aug 15, 2015; 7(8): 102-110 Published online Aug 15, 2015. doi: 10.4251/wjgo.v7.i8.102
Neoadjuvant or adjuvant therapy for gastric cancer
Laurent Quéro, Sophie Guillerm, Christophe Hennequin
Laurent Quéro, Sophie Guillerm, Christophe Hennequin, Department of Radiation Oncology, Saint Louis Hospital, 75010 Paris, France
Author contributions: Quéro L designed, researched and analyzed the literature, and helped write the paper; Guillerm S and Hennequin C analyzed the literature, and helped write the paper.
Conflict-of-interest statement: The authors have no conflict of interest related to the manuscript.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Laurent Quéro, MD, PhD, Department of Radiation Oncology, Saint Louis Hospital, 1 Avenue Claude Vellefaux, 75010 Paris, France. laurent.quero@sls.aphp.fr
Telephone: +33-142-499034 Fax: +33-142-494081
Received: March 10, 2015 Peer-review started: March 13, 2015 First decision: April 13, 2015 Revised: May 8, 2015 Accepted: July 11, 2015 Article in press: July 14, 2015 Published online: August 15, 2015 Processing time: 156 Days and 22.4 Hours
Abstract
Currently, there is no international consensus on the best treatment regimen for patients with advanced resectable gastric carcinoma. In the United States, where a limited lymph-node dissection is frequently performed, adjuvant chemoradiotherapy after surgery is the standard treatment. In Europe, intensified perioperative chemotherapy is commonly administered. In Japan and South Korea, postoperative S-1-based adjuvant chemotherapy after surgery with D2 lymph-node dissection is the standard treatment. Several ongoing trials are currently evaluating the optimal sequence of chemotherapy, radiotherapy, and surgery, as well as the place of targeted therapeutic agents in the treatment of advanced gastric carcinoma.
Core tip: Gastric cancer (GC) treatment is controversy, particularly between Asia and Western countries. In this paper, we have performed a systematic and up-to-date review of resectable GC treatment strategies and discussed different treatment options. We have also discribed ongoing clinical randomized phase 3 trials and future directions in GC treatment.
